Allergan plc is acquiring Repros Therapeutics Inc. for 67 U.S. cents per share in cash.
The deal is backed by the Repros Therapeutics board and is expected to close during the first quarter of 2018.
Repros Therapeutics focuses on developing small molecule drugs that treat male and female reproductive disorders.
Stifel Nicolaus & Co. Inc. is serving as the exclusive financial adviser to Repros in the deal, with Morgan Lewis & Bockius LLP acting as legal counsel.
Covington & Burling LLP is acting as Allergan's legal counsel.
